共 50 条
- [41] Safety and efficacy of JS']JSKN003 in patients with advanced/metastatic solid tumors: A first-in-human, dose-escalation, multicenter, open-label, phase I studyJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Park, John J.Gao, BoBeecroft, ClaireWilkinson, Kate JessicaParsonson, AndrewZhang, KarlYan, XiangyunWang, Ni
- [42] A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothened Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid TumorsCLINICAL CANCER RESEARCH, 2014, 20 (07) : 1900 - 1909Rodon, JordiTawbi, Hussein A.Thomas, Anne L.Stoller, Ronald G.Turtschi, Christian P.Baselga, JoseSarantopoulos, JohnMahalingam, DevalingamShou, YapingMoles, Melissa A.Yang, LinGranvil, CamilleHurh, EunjuRose, Kristine L.Amakye, Dereck D.Dummer, ReinhardMita, Alain C.
- [43] A first-in-human phase I study in patients with advanced and/or refractory solid malignancies to evaluate the safety of ATOR-1015, a CTLA-4 x OX40 bispecific antibody.JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)Yachnin, JeffreyUllenhag, Gustav J.Carneiro, AnaNielsen, DorteRohrberg, Kristoffer StaalKvarnhammar, Anne ManssonSchultz, LenaBageman, ErikaWennersten, CamillaRussell, Charlotte Astrid
- [44] First-in-human, phase 1, open-label, dose-escalation, dose-expansion study of ADCT901 as monotherapy in patients with select advanced solid tumorsJOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Harvey, R. DonaldFalchook, Gerald StevenNaqash, Abdul RafehKim, Joseph W.Dowlati, AfshinLe Bruchec, YvanCoudert, IsabelleErvin-Haynes, Annette L.Sommerhalder, David
- [45] A first-in-human, open-label, multi-center phase 1 study of TST003, a GREM 1 inhibitor, in subjects with locally advanced or metastatic solid tumorsCANCER RESEARCH, 2024, 84 (06)Rivera, Ismael RodriguezShen, LinKummar, ShivaaniBarve, MinalGerma, CarolineQi, ChuanChen, LeiMilata, JennyYao, JennyShen, LiZhu, Xuelian
- [46] A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myelomaBLOOD, 2012, 120 (03) : 552 - 559Zonder, Jeffrey A.Mohrbacher, Ann F.Singhal, Seemavan Rhee, FritsBensinger, William I.Ding, HanFry, JohnAfar, Daniel E. H.Singhal, Anil K.
- [47] Conteltinib (CT-707) in patients with advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, first-in-human phase 1 studyBMC Medicine, 20Puyuan XingQian ZhaoLi ZhangHanping WangDingzhi HuangPei HuYinghui SunYuankai Shi
- [48] Conteltinib (CT-707) in patients with advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, first-in-human phase 1 studyBMC MEDICINE, 2022, 20 (01)Xing, PuyuanZhao, QianZhang, LiWang, HanpingHuang, DingzhiHu, PeiSun, YinghuiShi, Yuankai
- [49] A phase I, open-label, multicenter, single-dose escalation and multi-dose study of a monoclonal antibody targeting CEACAM1 in subjects with selected advanced or recurrent malignancies.JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)Shapira, RoniWeber, Jeffrey S.Geva, RavitSznol, MarioKluger, Harriet M.Wong, Deborah J. L.Liang, Bertrand C.
- [50] Phase I dose-escalation, open-label study of HSP990 administered orally in adult patients with advanced solid malignancies.JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)De Mattos-Arruda, LeticiaSiu, Lillian L.Cortes, JavierBerge, YannRazak, Albiruni R. A.Ahnert, Jordi RodonCottura, EwaBedard, PhilippeAkimov, MikhailLu, HongPain, ScottKaag, AudreyDelord, Jean-Pierre